SOURCE: IDenta Corp.

August 30, 2007 11:28 ET

International Drug & Explosives Detection Firm IDenta Completes Testing of New Detector for Date Rape Drug -- Marketing Preparations Underway for Major Launch to Both Law Enforcement and Consumer Marketplaces

JERUSALEM--(Marketwire - August 30, 2007) - IDenta Corp. (PINKSHEETS: IDTA) today announced it has completed the testing of its latest drug detector designed to positively detect the presence of GHB, Gamma hydroxybutyrate, also known as 'The Date Rape Drug.' IDenta's preliminary research indicates that the GHB Detector has numerous applications both for law enforcement agencies who want to arrest the perpetrators of these dangerous substances, but as importantly, it is going to be marketed as a preventative safe guard for young women who are the targets of these very regrettable crimes.

In making the announcement, Yaacov Shoham, IDTA CEO, congratulated the company's chief scientist saying, "Baruch Glattstein again used his brilliance in forensic chemistry to solve a drug detection challenge whose illegitimate and usually undetected use causes great grief to its victims and their families. The IDenta GHB Drug Detector will add a valuable new dimension to our line of drug detection products for law enforcement and civilian marketplaces, and again confirms that IDenta is the world-wide leader in the development of drug and explosive detectors which yield no false-positives."

IDenta and its marketing team has started identifying numerous potential consumer sale points for the new product such as night clubs, vending machines, drug stores, through on-line merchandisers and on college campuses. Law enforcement agencies around the world are expected to readily embrace the detector as a valuable tool for sting operations in night club districts where the GHB drug is known to be present, and has been used in the commission of serious crimes such as assault and rape against unsuspecting victims.

Shoham continued, "If I were a parent with a daughter in college or who has moved away from home, this would be one of the first safety products I'd make sure they have in their purse. You cannot warn your children too much about dangers like this. It's better to be safe rather than to be sorry. That's why this new GHB detector has so much relevance. It has the potential to prevent a heinous crime from happening." The new GHB test will be easily administered in a two step (breaking only one ampoule) process using a chemically sensitive paper in conjunction with the company's patented ampoule packaging.

Development and product packaging of the IDenta GHB Drug Detector is already underway and the company is currently taking orders for delivery in mid-October. The final pricing structure is still being determined but is expected to be between $6 - $8 per unit. The official IDenta GHB Drug Detector product introduction will be at the California Narcotics Officers Association meeting to be held in November, in Reno, Nevada. At that time executives of IDenta and JANT Pharmacal, the company's U.S. marketing partner, will hold a formal news conference and provide further details of their plans for the entire line of IDenta-Accutest drug detectors.

ABOUT GHB

Gamma hydroxybutyrate (GHB) is an illicit chemical that has become a major cause of drug-related comas in the US and other countries. In fact, the number of GHB overdoses in the United States has now out-paced overdoses from MDMA (Ecstasy). GHB was rejected by the American medical community as a sleep aid in the 1960s, but has become popular among many people for its ability to depress consciousness, resulting in euphoria and intoxication. It is also touted on the Internet as a sleep aid, an anti-depressant and weight loss product, although these uses are not substantiated by reality and may carry a potentially deadly twist.

ABOUT IDENTA

Since 2003, IDenta Corporation has become recognized as a world-wide leader in the development of proprietary on-site drug and explosive detection kits. IDenta develops, manufactures and distributes products for the both professional and civil markets which consistently pass the highest qualifications and testing procedures of law enforcement and security agencies around the world. Information concerning IDenta's entire product line may be found at www.IDenta.biz.

DISCLAIMER

Certain of the statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements" that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management's expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.

Contact Information

  • For Investor Relations, lobbying interests or information concerning
    IDenta's products internationally contact:
    Yaacov Shoham
    CEO
    IDenta Corp.
    Tel: +972-52-6554487
    fpi@drugsdetector.com

    For Investor Relations in the US contact:
    Randy Jacobs
    Corporate Spokesman
    IDentaNews@sitcomllc.com
    1-800-316-9437

    For information about the Accutest - IDenta products in the US please
    contact:
    Mr. Eyal Golan
    COO
    JANT PHARMACAL CORPORATION
    16255 Ventura Blvd. #505
    Encino, CA 91436
    Toll Free: 800-676-5565
    www.accutest.net